Rx Label Format Changes Should Be Phased In Without "Highlights" - PhRMA
Executive Summary
FDA's prescription drug labeling initiative should proceed in areas where there is consensus between the agency and the pharmaceutical industry, the Pharmaceutical Research & Manufacturers of America said in comments on the proposed rule.
You may also be interested in...
FDA Makes Preemption Case Once And For All In Final Labeling Rule
The product liability preemption language in FDA's physician labeling rule applies to all drugs regardless of whether they are regulated by the final rule
FDA Makes Preemption Case Once And For All In Final Labeling Rule
The product liability preemption language in FDA's physician labeling rule applies to all drugs regardless of whether they are regulated by the final rule
Labeling And Liability: FDA Wary Of “Over-Warning,” “Piling On” By Lawyers
Trial lawyers should work with FDA to focus product liability actions on cases where manufacturers appear to be withholding information, Commissioner McClellan suggested during the National Community Pharmacists Association legislative conference May 19 in Washington, D.C